Can a smaller dose of arthritis drug tame COVID-19 lung inflammation?
NCT ID NCT04479358
First seen Apr 03, 2026 · Last updated May 23, 2026 · Updated 7 times
Summary
This study tested whether a low dose of tocilizumab, a drug used for arthritis, could help hospitalized COVID-19 patients with lung inflammation recover faster. It included 85 adults who were not on a breathing machine. The trial was stopped early, but the results may help guide how much of the drug is needed to treat severe COVID-19.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University of Chicago Medicine
Chicago, Illinois, 60637, United States
Conditions
Explore the condition pages connected to this study.